Gregory Enns, MD
Medical Biochemical Genetics · Palo Alto, CANPI 1508961897
Payments from drug & device makers
Across 389 payments — averaging $3118.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$463K
- PTC Therapeutics, Inc.$426K
- Astellas Pharma Inc$82K
- Travere Therapeutics, Inc.$60K
- Saol International Limited$49K
- Takeda Pharmaceuticals U.S.A., Inc.$39K
- plus $95K from 11 others
What the payments were for
- Consulting fees$67,61177%
- Speaking & faculty fees$19,29422%
- Travel & lodging$8681%
- Food & beverage$3870%
- Education$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 44 | $462,714 |
| PTC Therapeutics, Inc. | 138 | $426,037 |
| Astellas Pharma Inc | 37 | $82,213 |
| Travere Therapeutics, Inc. | 59 | $59,966 |
| Saol International Limited | 15 | $48,512 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $39,048 |
| Amgen | 16 | $32,322 |
| Amicus Therapeutics, Inc. | 17 | $14,798 |
| Ultragenyx Pharmaceutical Inc. | 12 | $12,880 |
| Mirum Pharmaceuticals, Inc. | 12 | $9,680 |
| Biomarin Pharmaceutical Inc. | 3 | $7,398 |
| AstraZeneca | 8 | $6,946 |
| UCB SA | 3 | $4,799 |
| Shire North American Group Inc | 2 | $3,840 |
| Sanofi US Services Inc. | 1 | $950 |
| Tanabe Pharma America, Inc. | 2 | $880 |
| Immedica Pharma US, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (820) Cholbam$27,550
- RAVICTI$20,062
- DOJOLVI$8,800
- POMBILITI$4,023
- OPFOLDA$4,023
- Kuvan$2,198
- Palynziq$2,198
- (815) Thiola$1,500
How this compares
Too few medical biochemical genetics providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical biochemical genetics in Palo Alto
- Annette FeigenbaumSan Diego$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.